"It is a sad irony that Australia has the highest melanoma rates in the world, yet we risk falling behind the U.S. and many European countries where this immunotherapy preventing melanoma recurrence in the majority of these high-risk patients is already available and subsidized. Australian patients would like certainty that they will be able to access affordable immunotherapy treatment which has proven successful in clinical trials and which many hundreds of patients have been forced to access on compassionate grounds or face costs of tens of thousands of dollars."

Georgina Long, co-medical director of Melanoma Institute Australia, which is urging the Australian government to undertake a timely review of immunotherapy treatments effective in preventing the spread of melanoma

"It's a great opportunity to see OS improvement in first- and second-line metastatic breast cancer – we haven't seen that in many years."

Sibylle Loibl, head of the clinical trials network German Breast Group, told the audience at the presidential symposium at the European Society of Medical Oncology that was devoted to breast cancer studies with two – MONARCH-2 and MONALEESA-3 – reporting an overall survival benefit of combining a CDK4/6 inhibitor with endocrine therapy Faslodex (fulvestrant) in metastatic hormone receptor-positive breast cancer in several different settings

"The platform is unique because gamma T cells bind to a target. You don't have to do gene editing to knock down T-cell receptors."

Anil Singhal, president and CEO, Adicet Bio Inc., whose company develops allogeneic cell therapies for cancer using gamma delta T cells and has raised $80 million from a series B round